DDInter1729 DDInter826
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®.
Sulindac {u} (Compound) causes {v} (Side Effect) Chills
Chills {u} (Side Effect) is caused by {v} (Compound) Glipizide
Sulindac {u} (Compound) causes {v} (Side Effect) Chills
Chills {u} (Side Effect) is caused by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glipizide
Sulindac {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Glipizide
Sulindac {u} (Compound) causes {v} (Side Effect) Dysuria
Dysuria {u} (Side Effect) is caused by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Sulindac {u} (Compound) causes {v} (Side Effect) Syncope
Syncope {u} (Side Effect) is caused by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Phentermine
Phentermine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Glipizide
Sulindac {u} (Compound) causes {v} (Side Effect) Gastrointestinal haemorrhage
Gastrointestinal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Aminoglutethimide
Aminoglutethimide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Sulindac {u} (Compound) binds {v} (Gene) AKR1B1
AKR1B1 {u} (Gene) regulates {v} (Gene) CASP10
CASP10 {u} (Gene) is upregulated by {v} (Compound) Glipizide
Sulindac (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Glipizide (Compound)
Sulindac (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Gliclazide (Compound) and Gliclazide (Compound) resembles Glipizide (Compound)
Sulindac (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Glyburide (Compound) and Glyburide (Compound) resembles Glipizide (Compound)
Sulindac (Compound) causes Dysuria (Side Effect) and Dysuria (Side Effect) is caused by Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glipizide
Sulindac (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Phentermine (Compound) and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Glipizide (Compound)
Sulindac (Compound) causes Gastrointestinal haemorrhage (Side Effect) and Gastrointestinal haemorrhage (Side Effect) is caused by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aminoglutethimide (Compound) and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Glipizide
Sulindac (Compound) binds AKR1B1 (Gene) and AKR1B1 (Gene) regulates CASP10 (Gene) and CASP10 (Gene) is upregulated by Glipizide (Compound)